124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
[
2 clinical trials,
7 drugs（DrugBank:
2 drugs),
1 target gene / 2 target pathways ]
Searched query = "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy", "Autosomal dominant cerebral artery disease with subcortical infarct and leukoencephalopathy", "Autosomal dominant cerebral artery disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2007-004370-55-IT | 14/12/2007 | 19 March 2012 | Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4 | Effects of tetrahydrobiopterin (6R-BH4) on flow-mediated dilation in CADASIL patients: a randomised controlled trial - CADASIL BH4 | CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), is a rare autosomal dominant disorder characterized by recurrent strokes starting in mid-adulthood and leading in some to severe motor disability with pseudobulbar palsy and dementia of the subcortical type MedDRA version: 9.1 Level: HLGT Classification code 10008804 Term: Chromosomal abnormalities and abnormal gene carriers | Product Name: Phenoptin Product Code: 6R-BH4 Pharmaceutical Form: Oral powder INN or Proposed INN: sapropterin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Oral powder Route of administration of the placebo: Oral use | AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE) | Not Recruiting | Female: yes Male: yes | Italy | |||||
| 2 | EUCTR2004-001162-40-FI | 08/03/2005 | 11 December 2017 | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL | Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia. MedDRA version: 7.0 Level: PT Classification code 10057678 | Trade Name: Aricept Product Name: Aricept Product Code: E2020 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: donepezil hydrochloride CAS Number: 120011-70-3 Current Sponsor code: E2020 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use | Eisai Ltd | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Finland;Spain;Germany;Italy;United Kingdom;Sweden |